|Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.|
|Jump to Full Text|
|PMID: 20492683 Owner: NLM Status: MEDLINE|
|BACKGROUND: Nuclear factor-kappaB (NF-kappaB) is constitutively activated in many cancers and plays a key role in promoting cell proliferation, survival, and invasion. Our understanding of NF-kappaB signaling in thyroid cancer, however, is limited. In this study, we have investigated the role of NF-kappaB signaling in thyroid cancer cell proliferation, invasion, and apoptosis using selective genetic inhibition of NF-kappaB in advanced thyroid cancer cell lines. RESULTS: Three pharmacologic inhibitors of NF-kappaB differentially inhibited growth in a panel of advanced thyroid cancer cell lines, suggesting that these NF-kappaB inhibitors may have off-target effects. We therefore used a selective genetic approach to inhibit NF-kappaB signaling by overexpression of a dominant-negative IkappaBalpha (mIkappaBalpha). These studies revealed decreased cell growth in only one of five thyroid cancer cell lines (8505C), which occurred through a block in the S-G2/M transition. Resistance to TNFalpha-induced apoptosis was observed in all cell lines, likely through an NF-kappaB-dependent mechanism. Inhibition of NF-kappaB by mIkappaBalpha sensitized a subset of cell lines to TNFalpha-induced apoptosis. Sensitive cell lines displayed sustained activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, defining a potential mechanism of response. Finally, NF-kappaB inhibition by mIkappaBalpha expression differentially reduced thyroid cancer cell invasion in these thyroid cancer cell lines. Sensitive cell lines demonstrated approximately a two-fold decrease in invasion, which was associated with differential expression of MMP-13. MMP-9 was reduced by mIkappaBalpha expression in all cell lines tested. CONCLUSIONS: These data indicate that selective inhibition of NF-kappaB represents an attractive therapeutic target for the treatment of advanced thyroid. However, it is apparent that global regulation of thyroid cancer cell growth and invasion is not achieved by NF-kappaB signaling alone. Instead, our findings suggest that other important molecular processes play a critical role in defining the extent of NF-kappaB function within cancer cells.|
|Kevin T Bauerle; Rebecca E Schweppe; Bryan R Haugen|
Related Documents :
|7857233 - Molecular genetics of thyroid and parathyroid neoplasia.
8139263 - Enhanced proteolytic activity is responsible for the aberrant morphogenetic development...
11506503 - An orthotopic xenograft model of human nonseminomatous germ cell tumour.
|Type: Journal Article; Research Support, N.I.H., Extramural Date: 2010-05-21|
|Title: Molecular cancer Volume: 9 ISSN: 1476-4598 ISO Abbreviation: Mol. Cancer Publication Date: 2010|
|Created Date: 2010-06-22 Completed Date: 2010-07-30 Revised Date: 2010-09-28|
Medline Journal Info:
|Nlm Unique ID: 101147698 Medline TA: Mol Cancer Country: England|
|Languages: eng Pagination: 117 Citation Subset: IM|
|Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Research Complex I, South Tower, Mail Stop 8106, 12801 East 17th Avenue, PO Box 6511, Aurora, CO 80045, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Cell Line, Tumor
Enzyme Inhibitors / pharmacology
NF-kappa B / antagonists & inhibitors*, genetics
Neoplasm Invasiveness / genetics*
Nitriles / pharmacology
Oleanolic Acid / analogs & derivatives, pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction / genetics
Sulfones / pharmacology
Thyroid Neoplasms / genetics*, metabolism*, pathology
|CA100560/CA/NCI NIH HHS; P30 CA 046934/CA/NCI NIH HHS|
|0/3-(4-methylphenylsulfonyl)-2-propenenitrile; 0/Enzyme Inhibitors; 0/NF-kappa B; 0/Nitriles; 0/Sulfones; 0/methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate; 508-02-1/Oleanolic Acid|
Journal ID (nlm-ta): Mol Cancer
Publisher: BioMed Central
Copyright ?2010 Bauerle et al; licensee BioMed Central Ltd.
Received Day: 8 Month: 3 Year: 2010
Accepted Day: 21 Month: 5 Year: 2010
collection publication date: Year: 2010
Electronic publication date: Day: 21 Month: 5 Year: 2010
Volume: 9First Page: 117 Last Page: 117
Publisher Id: 1476-4598-9-117
PubMed Id: 20492683
|Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion|
|Kevin T Bauerle12||Email: Kevin.firstname.lastname@example.org|
|Rebecca E Schweppe13||Email: Rebecca.email@example.com|
|Bryan R Haugen13||Email: firstname.lastname@example.org|
1Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado - Anschutz Medical Campus, Research Complex I, South Tower, Mail Stop 8106, 12801 East 17th Avenue, PO Box 6511, Aurora, CO 80045, USA
2Program in Cancer Biology, University of Colorado - Anschutz Medical Campus, Research Complex I, South Tower, Mail Stop 8104, 12801 East 17th Avenue, Aurora, CO 80045, USA
3University of Colorado Cancer Center, Aurora, CO 80045 USA
Thyroid cancer is the most common endocrine malignancy . Fortunately, a majority of patients are managed successfully with a combination of radioiodine and levothyroxine treatment following complete thyroidectomy. However, a subset of patients with advanced/dedifferentiated cancer have radioiodine-refractory disease with associated morbidity and mortality . Given the high frequency of activating mutations in the mitogen-activated protein kinase (MAPK) pathway achieved by rearrangements associated with the RET tyrosine kinase and activating point mutations in RAS and BRAF , therapies targeting this pathway have been an area of active investigation . Unfortunately, results from clinical studies regarding the overall efficacy of these therapies have been modest . Clearly, there remains a need for a better understanding of the molecular events involved in thyroid cancer initiation and progression to aid in the identification of novel therapeutic targets.
The nuclear factor-?B (NF-?B) family of transcription factors is comprised of RelA (p65), RelB, c-REL, NF-?B1/p50, and NF-?B2/p52, each of which is characterized by a Rel homology domain, which facilitates DNA-binding, homo- or heterodimerization of NF-?B family members, and interaction with inhibitory I?B proteins. A role for NF-?B in oncogenic progression has been described in a number of lymphoid malignancies and carcinomas, including thyroid, ovarian, breast, and hepatocellular carcinomas . Moreover, constitutive activation of NF-?B in tumors has been attributed to both excessive, chronic inflammation and activation by oncoproteins, as observed in hepatitis-induced hepatocellular carcinoma and melanoma, respectively [7,8]. NF-?B activation has also been implicated in acquired resistance to chemotherapy and radiation [9,10]. The end-product of NF-?B activation in cancer is believed to entail enhanced cell proliferation and invasion, as well as resistance to apoptosis induced by tumor surveillance mechanisms and various therapeutic modalities [10,11].
While the two primary modes of NF-?B activation are similar in that they culminate in NF-?B-dependent gene regulation through nuclear translocation of NF-?B dimers, the pathways are distinguished by the differential requirement of the trimeric I?B kinase (IKK) complex, which is composed of two kinase subunits, IKK? and IKK?, and a regulatory, scaffolding subunit IKK?. The classical pathway of activation requires phosphorylation of I?B proteins by the trimeric IKK complex, resulting in proteasome-dependent degradation of the inhibitory proteins and nuclear translocation of the classical p50/p65 heterodimer. The alternative pathway involves cleavage of the NF-?B2 precursor protein into the functional p52 subunit, which may then complex with RelB. This pathway is dependent on phosphorylation of the NF-?B2 precursor by IKK? dimers .
To date, several studies have employed the use of pharmacologic inhibitors of NF-?B to establish a role for NF-?B in thyroid cancer cell growth and invasion [13-17]. However, these results should be interpreted with caution given the potential for off-target effects of many of these drugs. In this report, we used a selective genetic inhibitor of NF-?B (mI?B?) in a panel of authenticated thyroid cancer cell lines . We demonstrate that inhibition of NF-?B decreases thyroid cancer cell proliferation and invasion, while promoting TNF?-induced apoptosis. These findings are observed in only a subset of thyroid cancer cell lines and appear to be associated with distinct regulatory mechanisms.
Pharmacologic inhibitors of NF-?B have been widely used to investigate the functional consequences of constitutive NF-?B activation in cancer. Many of these inhibitors prevent phosphorylation and degradation of I?B? by blocking IKK complex activity . We initially tested three NF-?B inhibitors, Bay 11-7082 (1 ?M), IKK Inhibitor VII (1 ?M), and CDDO-Me (0.25 ?M), to investigate the role of NF-?B in thyroid cancer cell growth. The concentrations used in these experiments were based on studies using these compounds to document NF-?B-dependent effects on cell growth [20-22]. Each compound demonstrated inhibition of IKK? activity by blocking TNF?-induced nuclear localization of p65 in a dose-dependent manner (data not shown).
A panel of papillary thyroid cancer (PTC) (BCPAP, TPC1) and anaplastic thyroid cancer (ATC) (SW1736, C643) cell lines were used. These cell lines harbour different activating mutations in the MAPK pathway, including the HRAS G13R mutation (C643), the BRAF V600E mutation (BCPAP, SW1736), and the RET/PTC1 rearrangement (TPC1) . Treatment with CDDO-Me, Bay 11-7082, and IKK Inhibitor VII inhibited growth in all cell lines. Interestingly, the effects of the inhibitors on TPC1 (RET/PTC1) and C643 (HRAS) cells were quite variable, while the cells harbouring a BRAF V600E mutation (BCPAP and SW1736) displayed similar degrees of sensitivity to each of the inhibitors (Figure 1). The variable growth inhibition of these cell lines in response to treatment with three NF-?B inhibitors suggests that these inhibitors may exert their growth inhibitory effects through off-target mechanisms that are independent of NF-?B signaling.
Based on the variable growth inhibition by different pharmacologic inhibitors of NF-?B, a selective genetic approach to inhibit NF-?B signaling was used. Specifically, expression of a dominant-negative I?B? (mI?B?) [23,24], which is resistant to IKK-induced phosphorylation and proteasomal degradation, was carried out by adenoviral transduction . This results in cytoplasmic sequestration and transcriptional inactivation of the NF-?B family of proteins. For these studies, we added the 8505C ATC cell line, which is characterized by the BRAF V600E mutation . Adenoviral-mediated expression of mI?B? was assessed by Western blot analysis following transduction of thyroid cancer cell lines with a multiplicity of infection (MOI) ranging from 5-250 (Figure 2A). Expression levels of mI?B? varied substantially across the five cell lines tested, likely because of the efficiency of viral transduction. Indeed, a direct correlation between transduction efficiency, which was assessed by adenoviral-mediated expression of GFP, and mI?B? expression was observed (Figure 2A and data not shown).
The five thyroid cancer cell lines demonstrated different basal levels of NF-?B transcriptional activity as determined by an NF-?B-responsive luciferase reporter, with the BCPAP and 8505C cell lines exhibiting the highest levels of NF-?B activity (Figure 2B). Basal NF-?B activity did not correlate with tumor type (ATC vs. PTC). Figure 2C shows that NF-?B transcriptional activity could be inhibited by greater than 90% in each of the five cell lines. The degree of inhibition at a given MOI correlated with mI?B? protein expression in each of the cell lines. Importantly, transduction of cells with Ad-GFP at the same MOI had no effect on NF-?B transcriptional activity (data not shown). These results demonstrate effective inhibition of constitutive NF-?B activity in our panel of 5 thyroid cancer cell lines.
We next investigated the role of NF-?B in thyroid cancer cell proliferation and survival. Thyroid cancer cells were transduced with either Ad-mI?B? or Ad-GFP at an MOI of 50 or 200, and growth was assessed after 5 days by automated viable cell counting. Transduction with control Ad-GFP was performed to monitor transduction efficiency and control for the effects of adenoviral transduction on cell growth. Inhibition of NF-?B by mI?B? expression did not decrease thyroid cancer cell proliferation or survival in four of the five cell lines tested (Figure 3), even under conditions of serum starvation (0.5% FBS) (data not shown). However, the 8505C cell line showed a 42% decrease in cell growth in response to NF-?B inhibition when transduced with an MOI of 50. 8505C cell growth was inhibited with an MOI as low as 5 (36% inhibition; data not shown), confirming that NF-?B-dependent regulation of 8505C cell growth was not due to higher levels of mI?B? expression (Figure 2A).
To determine the mechanisms governing growth inhibition by mI?B? in the 8505C cell line, measures of apoptosis and cell cycle analysis were performed. Cleaved poly (ADP-ribose) polymerase (PARP), a measure of apoptosis, was undetectable by Western blot analysis, suggesting that NF-?B inhibition does not induce apoptosis (data not shown). However, flow cytometry revealed a significant increase in the number of cells in S-phase following mI?B? expression. This finding corresponded with a 28% decrease in the number of mI?B?-expressing cells in G2/M, indicating a block in the S-phase to G2/M transition (Figure 4A). Western blot analysis (Figure 4B) of cell cycle regulatory proteins demonstrated no regulation of cyclin A protein levels and only a small decrease in phospho-cdc2 levels in response to NF-?B inhibition. Notably, NF-?B inhibition resulted in an increase in p21 levels and decrease in the levels of cyclin B1, suggesting that the transition from S-phase to G2/M in 8505C cells is mediated by NF-?B-dependent regulation of cyclin B1 and p21. Based on the profound growth arrest observed in 8505C cells by NF-?B inhibition, this cell line was not used in subsequent studies of TNF?-induced apoptosis or invasion.
TNF? signaling is responsible for activation of numerous pro-apoptotic pathways, which can be opposed by pro-survival NF-?B signaling through activation of the IKK complex . Figure 5A (GFP) shows that thyroid cancer cell lines are resistant to TNF?-induced apoptosis, as cells transduced with control Ad-GFP displayed no significant decrease in cell viability following treatment with TNF?. We also observed that TNF? treatment resulted in the nuclear accumulation of p65, suggesting that increased NF-?B signaling promotes resistance to TNF?-induced apoptosis (Figure 5B; GFP). We therefore predicted that inhibition of TNF?-induced nuclear translocation of p65 would sensitize thyroid cancer cell lines to TNF?-induced apoptosis. As expected, expression of mI?B? greatly reduced nuclear translocation of p65 due to TNF? treatment, and lower levels of basal nuclear p65 were also observed in SW1736, TPC1, and C643 cells transduced with Ad-mI?B? when compared to control (Figure 5B). Interestingly, TNF? treatment in combination with NF-?B inhibition decreased cell viability in only two of the cancer cell lines (SW1736 and TPC1) (Figure 5A). Accordingly, levels of cleaved PARP, a marker of apoptosis, were increased after treatment with TNF? in SW1736 and TPC1 cells expressing mI?B? but not in cells expressing control GFP (Figure 5C). Cleaved PARP was not detected in TNF?/mI?B? resistant BCPAP or C643 cells (data not shown).
To investigate the mechanisms by which only a subset of cell lines are sensitized to the combined pro-apoptotic effects of TNF? treatment and NF-?B inhibition, we examined activation of the pro-apoptotic JNK/SAPK pathway. Activation of the JNK pathway was assessed by Western blot analysis with an antibody specific to the activated, phosphorylated (Thr183/Tyr185) forms of JNK1/2. Transient activation of JNK/SAPK pathway in control GFP-transduced cells was only observed in the TPC1 cell line (Figure 6). Interestingly, sustained activation of the JNK pathway was observed in response to TNF? treatment only in mI?B?-expressing cell lines (SW1736, TPC1) that were sensitive to the pro-apoptotic effects of combined TNF? treatment and genetic inhibition of NF-?B signaling (Figure 5A and 6).
An understanding of the role of NF-?B signaling in regulation of thyroid cancer cell invasion is particularly relevant given the nature of the disease and the mortality associated with locally invasive and metastatic tumors. Therefore, we assessed the role of NF-?B in thyroid cancer cell invasion using Matrigel-coated transwell assays. In these studies, cells (BCPAP, SW1736, TPC1, C643) were transduced with either Ad-GFP or Ad-mI?B? and allowed to invade for 24 hours. Control-transduced C643 cells were the most invasive (~450 cells/field), while TPC1 cells were the least invasive (~150 cells/field). SW1736 and BCPAP cells were moderately invasive (~300 cells/field) (data not shown). Invasion by the SW1736 and TPC1 cell lines was significantly inhibited (46% and 44%, respectively) by mI?B? expression, while BCPAP and C643 cells were resistant (Figure 7).
To investigate the mechanism by which NF-?B regulates thyroid cancer cell invasion, we performed quantitative RT-PCR to examine the NF-?B-dependent regulation of the matrix metalloproteinase (MMP) -2, MMP-9, and MMP-13 (Figure 8). Figure 8 shows that transcript levels of MMP-2 and MMP-13 were not significantly affected by mI?B? expression after 48 hours. Interestingly, both resistant cell lines (BCPAP, C643) expressed basal MMP-13 transcripts levels that were at least two-fold higher (p<0.05) than either of the sensitive cell lines, while MMP-2 levels were similar across all cell lines (Figure 8A, B). Figure 8C shows that MMP-9 transcript levels were decreased significantly by NF-?B inhibition in both the resistant [BCPAP (~2.5 fold), C643 (~7 fold)] and sensitive [SW1736 (~4.5 fold), TPC1 (~3 fold)] cell lines.
In this report, we have used a selective genetic inhibitor of NF-?B signaling to determine the effects of this pathway on proliferation, apoptosis, and invasion in a panel of ATC and PTC thyroid cancer cell lines. Our data indicate that NF-?B does not have one common role in the regulation of proliferation, apoptosis, or invasion in advanced thyroid cancer and that sensitivity to NF-?B inhibition does not correlate with baseline levels of NF-?B transcriptional activity. Instead, we have demonstrated that some cancer cells depend on NF-?B signaling for proliferation (8505C), while others require it for invasion and resistance to TNF?-induced apoptosis (TPC1, SW1736). Furthermore, some cell lines are not dependent on NF-?B signaling for these basic cancer properties (BCPAP, C643).
The hallmarks of cancer include self-sufficiency in growth signals, resistance to anti-growth signals, evasion of apoptosis, unlimited replication potential, sustained angiogenesis, and acquisition of metastatic/invasive potential . Activation of NF-?B signaling in cancer is a critical mediator in the majority, if not all, of these processes . This theory has led to numerous studies aimed at identifying a link between NF-?B signaling and thyroid cancer growth and progression. Using the NF-?B inhibitor DHMEQ, Yamashita and colleagues showed decreased tumor growth, cancer cell invasion, increased apoptosis, as well as TNF?- and taxane-induced apoptosis in a single ATC cell line [13,14]. Liu and Xing demonstrated synergistic inhibition of cell proliferation in a panel of thyroid cancer cell lines when combining a MEK1/2 inhibitor with PS1145, an IKK complex inhibitor . Another study by Zhu and colleagues showed that a small molecule triptolide inhibited angiogenesis, invasion, and proliferation in a single ATC cell line and further suggested that this was associated with inhibition of NF-?B transcriptional activity . The primary genetic study linking NF-?B to thyroid cancer was performed by Pacifico and colleagues via stable overexpression of mI?B? in the FRO ATC cell line. In doing so, they showed that NF-?B promotes in vivo tumor formation, growth in soft-agar, and resistance to chemotherapy-induced apoptosis . Our studies have extended the use of a genetic model to identify a role for NF-?B signaling in a panel of authenticated thyroid cancer cell lines, and in doing so, we have advanced knowledge of the role of NF-?B in thyroid cancer proliferation, apoptosis, and invasion.
Previous studies in cancer models, including thyroid cancer, have cited a role for NF-?B in malignant cell proliferation by transcriptional regulation of cyclin D1, CDK2, cyclin E and c-Myc . Using a selective genetic model, however, we have shown that NF-?B regulates cancer cell proliferation in only one of five cell lines tested (Figure 3). Cell cycle arrest was induced in the 8505C ATC cell line by blocking the transition from S-phase to G2/M (Figure 4A), representing a novel mechanism for the regulation of thyroid cancer cell proliferation by NF-?B. While cyclin A is critical for progression through S-phase , protein levels were not affected by NF-?B inhibition (Figure 4B). Similarly, dephosphorylation of cdc2 at Tyr 15, which is predicted upon entry into G2/M , was observed (Figure 4B). However, protein levels of cyclin B1, which is necessary for the entry into and progression through G2-phase and mitosis , were decreased following NF-?B inhibition (Figure 4B). Interestingly, this finding was associated with increased levels of the cyclin-dependent kinase inhibitor, p21 (Figure 4B). Indeed, increased levels of p21 have been shown to mediate p53-induced cell cycle arrest in response to genotoxic stress by down-regulation of cyclin B1 expression . NF-?B signaling has also been shown to inhibit cell cycle arrest by decreasing p21 levels in osteoblasts  and normal epithelial cells in a manner dependent on the phosphatidylinositol-3-kinase (PI3K) pathway . Similar observations have been made in prostate cancer cells , thereby providing substantial evidence for a mechanism by which decreased NF-?B signaling in the 8505C cell line leads to decreased cyclin B1 expression in a p21-dependent manner.
The ability of NF-?B signaling to deregulate programmed cell death by apoptosis is a major mechanism by which NF-?B exerts its pro-tumorigenic functions. This effect is often achieved by transcriptional regulation of anti-apoptotic genes, including Bcl-2 family members [11,13,34]. Starenki and colleagues demonstrated that inhibition of NF-?B by DHMEQ in thyroid cancer cells induced spontaneous apoptosis through down-regulation of cIAP-1, cIAP-2, and XIAP . However, our studies indicate that genetic inhibition of NF-?B in a panel of thyroid cancer cell lines does not induce spontaneous apoptosis even under conditions of serum-starvation (Figure 3 and data not shown). Pacifico and colleagues obtained similar results when stably overexpressing mI?B? in the FRO ATC cell line .
NF-?B signaling is critical for blocking apoptosis following ligand binding by members of the tumor necrosis factor receptor (TNFR) superfamily. Members of this family induce activation of the extrinsic apoptosis pathway by a cytoplasmic death domain. These receptors include the classical receptor TNFR1, which binds the inflammatory cytokine TNF?, as well as Fas, TNF-related apoptosis-inducing ligand (TRAIL)-receptor 1, and TRAIL-R2 [35,36]. Pro-apoptotic effects of TNFR1 activation by TNF? are two-fold. First, receptor activation induces formation of complex II, which ultimately triggers mitochondrial release of cytochrome c, and second, activation of the JNK/SAPK pathway results in downstream release of Smac/Diablo into the cytosol to activate caspase 8. However, under conditions in which NF-?B signaling is intact, the pro-apoptotic functions of TNFR1 activation are often masked due, in large part, to the survival functions imparted by NF-?B. Indeed, studies have shown that abrogation of NF-?B signaling can enhance TNF?-induced apoptosis . Our results demonstrate that inhibition of NF-?B signaling promotes TNF?-induced apoptosis in a subset of cell lines, and this finding is associated with a sustained activation of JNK in response to TNF?-treatment in the presence NF-?B inhibition in these cell lines (SW1736, TPC1) (Figure 6). Sustained activation of JNK was not observed in the resistant cell lines (BCPAP, C643). These data suggest a mechanism by which sensitization of thyroid cancer cell lines to the combinatorial effects of TNF?-treatment and NF-?B inhibition requires activation of the JNK pathway that may, in fact, be cell line and tumor specific. However, the exact mechanism by which differential activation of JNK remains unclear and may involve variable regulation of upstream signaling components. One study showed that breast cancer cells, which are typically resistant to TNF?-induced apoptosis, demonstrated enhanced apoptosis and prolonged activation of JNK when expressing mI?B? . The authors were able to block induction of apoptosis via treatment with an inhibitor of JNK activation. In our studies, however, treatment with the JNK inhibitor, SP600125, alone inhibited growth of our thyroid cancer cell lines (data not shown), likely due to off-target mechanisms associated with the compound, as described by Bain and colleagues . Another study reported a cell line-specific, differential activation of JNK following treatment of two oral squamous cell carcinoma (OSCC) lines with TRAIL, another ligand known to activate the TNFR superfamily . While this study did not involve inhibition of NF-?B, their basic findings were consistent with ours, in that a strong induction of JNK activation was necessary for OSCC sensitivity to TRAIL-induced apoptosis.
MMPs belong to a family of endopeptidases, which are classified based on their specificity for particular extracellular matrix substrates, and are believed to play a critical role in the acquisition of metastatic potential by cancer cells by promoting migratory/invasive potential. MMP regulation is governed by numerous oncogenic processes, including constitutive activation of NF-?B [40,41]. In the current study, we have demonstrated differential regulation of invasion by NF-?B and evaluated the expression levels of MMP-2, -9, and -13. These MMPs are significant in that they are regulated by NF-?B (MMP-9) and expressed ubiquitously in thyroid cancer cell lines (MMP-13) [41,42]. Also, expression of both MMP-2 and MMP-9 is increased in neoplastic thyroid cell lines when compared to normal thyroid cell lines [41,42]. Only MMP-9 displayed significantly decreased transcript levels in response to NF-?B inhibition (Figure 8C). This finding is important, however, given the correlation with MMP-9 expression and poor prognosis in breast and prostate cancer. No significant regulation of MMP-2 or MMP-13 was observed. Interestingly, MMP-13 transcript levels at baseline were at least two-fold higher in the resistant cell lines (BCPAP, C643) when compared to transcript levels in sensitive cell lines (SW1736, TPC1) (Figure 7; Figure 8B). Further studies will be required to determine the precise mechanisms by which NF-?B regulates invasion in thyroid cancer cells. Nonetheless, the insights provided in this study clearly demonstrate a role for NF-?B in thyroid cancer cell invasion.
In conclusion, our results demonstrate an important and diverse role for NF-?B signaling in thyroid cancer. Interestingly, these effects are not observed across an entire panel of thyroid cancer cell lines, and they are not associated with a particular mutational status or histological tumor classification. Here, we show distinct roles for NF-?B signaling in the regulation of thyroid cancer cell proliferation, resistance to TNF?-induced apoptosis, and invasion. Decreased proliferation through blockade of the S-phase to G2/M transition is observed in response to NF-?B inhibition. Furthermore, NF-?B likely mediates cancer cell invasion, at least in part, by driving MMP-9 transcription. Finally, sensitivity to TNF?-induced apoptosis by inhibition of NF-?B is associated with sustained activation of the JNK pathway. Taken together, these results suggest that novel therapeutics targeting NF-?B may be of clinical utility in the treatment of advanced thyroid cancer, but this is not likely to be of global use in the treatment of all thyroid cancers. Downstream markers may identify which cell lines, and ultimately which patients, may respond to inhibitors of this important pathway.
The BCPAP, SW1736, 8505C, TPC1, and C643 thyroid cancer cell lines were maintained for 10-20 passages at 37?C and 5% CO2 in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Hyclone). The BCPAP and 8505C cell lines were kindly provided by Dr. M. Santoro (Medical School, University "Federico II" of Naples, Naples, Italy). The SW1736 and C643 cell lines were kindly provided by Dr. K. Ain (University of Kentucky), with permission from Dr. N-E Heldin (University Hospital, S-751 85 Uppsala, Sweden). The TPC1 cell line was kindly provided by Dr. S. Jhiang (Ohio State University). Cell lines were routinely profiled by Short Tandem Repeat analysis and are consistent with our previously published profiles .
The NF-?B inhibitors, IKK Inhibitor VII (Calbiochem), Bay 11-7082 (Calbiochem), and CDDO-Me (kindly provided by Dr. M. Sporn, Dartmouth Medical School, Hanover, NH), were dissolved in DMSO at a final concentration of 10 mM.
Expression of mI?B? was achieved by adenoviral transduction. Ad-mI?B? and Ad-GFP were kindly provided by Dr. J. DeGregori (University of Colorado Denver, Anschutz Medical Campus, Aurora, CO) . For transduction, cells were trypsinized and resuspended in RPMI supplemented with 1% FBS, transduced in suspension for 1 hour with gentle agitation, and plated at the indicated cell number in RPMI supplemented with 10% FBS.
A 3?-?B NF-?B-responsive luciferase reporter comprised of 3 tandem repeats from the MHC class I enhancer and a ?-galactosidase reporter driven by the actin promoter (actin ?-gal) were kindly provided by Drs. A. Baldwin (University of North Carolina) and M. Karin (University of California, San Francisco), respectively. Transfections were carried out using Lipofectamine 2000 (Invitrogen), according to manufacturer's protocol. Briefly, thyroid cancer cells (1.0 ? 105) were transduced with either Ad-GFP (as an appropriate control) or Ad-mI?B? at the indicated MOI and seeded in 24-well plates 24 hours prior to transfection. DNA (0.8 ?g) and Lipofectamine were diluted in Optimem at a Lipofectamine:DNA ratio of 2.5:1. After 4-6 hours, the media containing the complexes was removed from cells and replaced with fresh RPMI supplemented 10% FBS. Cells were harvested at 24 hours post-transfection in passive lysis buffer (PLB; Promega) and subjected to a single freeze-thaw cycle. The Luciferase Assay System (Promega) and Luminescent ?-galactosidase Detection Kit II (Clontech) were used to assay luciferase and luminescent ?-galactosidase activities, respectively. Luciferase relative light units (RLU) were normalized to luminescent ?-galactosidase activity (RLU) to obtain a normalized measure of NF-?B transcriptional activity.
To prepare whole-cell extracts, cells were washed once with phosphate-buffered saline (PBS) and harvested in extraction buffer (EB; 1% Triton X-100, 10 mM Tris, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 2 mM Na3VO4 supplemented with 1? complete protease inhibitors (Roche Diagnostics). Cellular debris was then removed by centrifugation at 13,000 rpm for 10 minutes at 4?C. Nuclear and cytoplasmic extracts were prepared using the Nuclear Extract Kit (Active Motif), according to manufacturer's instructions. Extracts (40 ?g) were resolved on 10% SDS-PAGE and transferred to Immobilon-P transfer membranes (Millipore). Membranes were probed with primary antibodies against PARP (rabbit polyclonal, AB16661, Millipore), cleaved PARP (mouse monoclonal, AB3565, Millipore), ?-tubulin (mouse monoclonal, DM1A, Calbiochem), RelA (mouse monoclonal, F-6, Santa Cruz), I?B? (rabbit polyclonal, FL, Santa Cruz), ppSAPK/JNK (mouse monoclonal, #9255s, Thr-183/Tyr-185, Cell Signaling), SAPK/JNK (rabbit polyclonal, #9252, Cell Signaling), cyclin B1 (rabbit polyclonal, #4138, Cell Signaling), cyclin A (mouse monoclonal, #4656, Cell Signaling), and p21 (rabbit monoclonal, #2947, Cell Signaling) in blocking buffer (5% nonfat dry milk in 20 mM Tris, pH 7.4, 138 mM NaCl, 0.1% Tween (TBST)) overnight at 4?C. Membranes were washed with TBST and incubated with secondary goat anti-rabbit or goat anti-mouse horseradish peroxidase-conjugated antibody (GE Healthcare) for 3 h at room temperature. Immunoreactivity was visualized by enhanced chemiluminescence detection (Pierce). Blots were stripped and re-probed, where indicated, using Re-Blot Plus Mild (Millipore).
For studies with pharmacologic inhibitors of NF-?B, thyroid cancer cells (1.5 ? 104 - BCPAP, C643, SW1736, and 8505C; 7.5 ? 103 - TPC1) were seeded in 6 cm plates. The following day, cells were treated with either vehicle (DMSO), IKK Inhibitor VII (1 ?M), Bay 11-7082 (1 ?M), or CDDO-Me (0.25 ?M). Cells were replenished with fresh RPMI (10% FBS) supplemented with drug or vehicle after two days. After a total of five days of treatment, the media was collected, and adherent cells were washed with PBS and harvested by trypsinization. Cells were then combined with the collected media, centrifuged at 1,000 rpm for 5 minutes, and resuspended in 0.5 ml PBS. Viable cells were then counted using the Vi-CELL Coulter Counter (Beckman, Inc). For viral transduction studies, cells (1.5 ? 104 - BCPAP, C643, SW1736, and 8505C; 7.5 ? 103 - TPC1) were transduced as described above with either Ad-GFP or Ad-mI?B? at an MOI of 50 or 200 and then seeded in 6 cm plates. On the following day, the media was replaced with fresh RPMI (10% FBS). The media was again replaced with fresh RPMI (10% FBS) two days later. Five days post-transduction, media and cells were collected, and viable cell number was assessed as described above by ViCell counting.
8505C thyroid cancer cells (7.5 ? 105) were transduced as described above with either Ad-GFP or Ad-mI?B? at an MOI of 25. Cells were then seeded in 10 cm dishes in RPMI (10% FBS). After 48 hours, adherent cells were harvested by trypsinization and washed with PBS. Cell pellets were resuspended in a saponin/propidium iodide solution (0.3% saponin, 25 ?g/mL propidium iodide, 0.1 mM EDTA, and 10 ?g/mL RNase A). Cells were incubated at 4?C for 8 hours, and cell cycle distribution was determined by flow cytometry using a Beckman Coulter FC500 at the University of Colorado Cancer Center Flow Cytometry Core. ModFit LT (Verity Software House) was used for cell cycle modeling and doublet discrimination.
Thyroid cancer cells were transduced with either Ad-GFP (as an appropriate control) or Ad-mI?B? at an MOI sufficient to achieve greater than 90% of NF-?B transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Cells (2,500/well for TPC1; 5,000/well for BCPAP, SW1736, and C643) were seeded in octuplicate into 96-well plates in RPMI supplemented with 10% FBS. Cells were treated the next day with medium containing 10 ng/ml TNF? (GenScript) (or vehicle) for three days, and cell viability was assayed after three days. Cell viability was measured per manufacturer's instructions using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega) with an MRX Microplate Reader (Dynatech Laboratories) and the Revelation software at an absorbance of 490 nm.
Apoptosis was assessed by Western blot analysis of cleaved PARP, as described above. For these studies, cells were serum-starved overnight prior to treatment. Cleaved PARP is the 89 kD cleavage product of poly (ADP-ribose) polymerase 1 (PARP1), which serves as a caspase substrate during the early stages of apoptosis .
Thyroid cancer cells were transduced as described above with either Ad-GFP or Ad-mI?B? at an MOI sufficient to achieve greater than 90% inhibition of NF-?B transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Twenty-four hours later, the media was replaced with fresh RPMI (0.1% FBS). After 6 hours, cells (1.0 ? 105) were harvested and seeded in the upper chambers of Matrigel-coated transwell chambers (24-well, 8 ?M pore size; BD Biosciences) in RPMI (0.1% FBS). Cell invasion was promoted by the presence of RPMI supplemented with 10% FBS in the lower chamber. After 24 hours, non-invading cells on the top chamber were removed by scraping with a cotton swab, and invading cells on the lower surface were fixed with methanol and stained with 3 ?g/mL 4',6-diamidino-2-phenylindole (DAPI; Invitrogen). Cell invasion was assessed by counting DAPI-stained nuclei in five microscopic fields under 10? magnification using the Metamorph software (Molecular Devices) and Nikon microscope.
Thyroid cancer cells were transduced with either Ad-GFP (as an appropriate control) or Ad-mI?B? at an MOI sufficient to achieve greater than 90% of NF-?B transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Total RNA was isolated from the cells after 48 hours using the PerfectPure RNA Cultured Cell Kit (5 Prime) as per the manufacturer's protocol. The mRNA levels of MMP-2, -9, and -13 were measured by real-time quantitative reverse transcription-PCR using ABI PRISM 7700.
MMP-2; TaqMan Gene Expression Assay ID: HS00234422_m1.
MMP-9; Sense-CCCGGACCAAGGATACAGTTT, Antisense- GAATGATCTAAGCCCAGCGC, Probe-CCTCGTGGCGGCGCATGAG
MMP-13; Sense-TGGCATTGCTGACATCATGA; Antisense-GCCAGAGGGCCCATCAA, Probe-TGGAATTAAGGAGCATGGCGACTTCTACC
Amplification reactions and thermal cycling conditions were optimized for each primer-probe set and carried out by the University of Colorado Cancer Center QRT-PCR Core. A standard curve was generated using the fluorescent data from the 10-fold serial dilutions of control RNA. This was then used to calculate the transcripts levels of MMP-2, -9, and -13 in the RNA samples. Quantities of MMP-2, -9, and -13 in samples were normalized to the corresponding 18S rRNA (PE ABI, P/N 4308310).
Statistical significance between groups was determined using the two-tailed t-test (GraphPad Prism) [p < 0.05 (*); p < 0.01 (**); p < 0.001 (***)]
The authors declare that they have no competing interests.
KTB designed and performed the experiments, interpreted data, assembled the figures, and drafted the manuscript. BRH conceived of the study and directed the research, with assistance from RES. RES and BRH critically reviewed the manuscript, which was approved by all authors.
This work was supported by NCI CA100560 (BRH) and Mary Rossick Kern and Jerome H Kern Endowment (BRH). Cell cycle studies were performed by the University of Colorado Cancer Center Flow Cytometry Core supported by NIH grant P30 CA 046934. Quantitative RT-PCR studies were performed by the University of Colorado Cancer Center QRT-PCR Core.
|Parker SL,Tong T,Bolden S,Wingo PA,Cancer statisticsCA Cancer J ClinYear: 19974752710.3322/canjclin.47.1.58996076|
|Haugen BR,Management of the patient with progressive radioiodine non-responsive diseaseSemin Surg OncolYear: 199916344110.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-29890738|
|Nikiforov YE,Thyroid carcinoma: molecular pathways and therapeutic targetsMod PatholYear: 200821Suppl 2S37S4310.1038/modpathol.2008.1018437172|
|Pfister DG,Fagin JA,Refractory thyroid cancer: a paradigm shift in treatment is not far offJ Clin OncolYear: 2008264701470410.1200/JCO.2008.17.368218541893|
|Sherman SI,Molecularly targeted therapies for thyroid cancersEndocr PractYear: 20091560561110.4158/EP09131.RAR19546052|
|Pacifico F,Leonardi A,NF-kappaB in solid tumorsBiochem PharmacolYear: 2006721142115210.1016/j.bcp.2006.07.03216956585|
|Arsura M,Cavin LG,Nuclear factor-kappaB and liver carcinogenesisCancer LettYear: 200522915716910.1016/j.canlet.2005.07.00816125305|
|Liu J,Suresh Kumar KG,Yu D,Molton SA,McMahon M,Herlyn M,Thomas-Tikhonenko A,Fuchs SY,Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cellsOncogeneYear: 2007261954195810.1038/sj.onc.120999417001349|
|Escarcega RO,Fuentes-Alexandro S,Garcia-Carrasco M,Gatica A,Zamora A,The transcription factor nuclear factor-kappa B and cancerClin Oncol (R Coll Radiol)Year: 20071915416117355113|
|Brzoska K,Szumiel I,Signaling loops and linear pathways: NF-kappaB activation in response to genotoxic stressMutagenesisYear: 2009241810.1093/mutage/gen05618832076|
|Naugler WE,Karin M,NF-kappaB and cancer-identifying targets and mechanismsCurr Opin Genet DevYear: 200818192610.1016/j.gde.2008.01.02018440219|
|Karin M,Nuclear factor-kappaB in cancer development and progressionNatureYear: 200644143143610.1038/nature0487016724054|
|Starenki DV,Namba H,Saenko VA,Ohtsuru A,Maeda S,Umezawa W,Yamashita S,Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicinClin Cancer ResYear: 2004106821682910.1158/1078-0432.CCR-04-046315501958|
|Meng Z,Mitsutake N,Nakashima M,Starenki D,Matsuse M,Takakura S,Namba H,Saenko V,Umezawa K,Ohtsuru A,Yamashita S,Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cellsEndocrinologyYear: 20081495357536510.1210/en.2008-027918653704|
|Zhu W,Ou Y,Li Y,Xiao R,Shu M,Zhou Y,Xie J,He S,Qiu P,Yan G,A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathwayMol PharmacolYear: 20097581281910.1124/mol.108.05260519158360|
|Mitsiades CS,McMillin D,Kotoula V,Poulaki V,McMullan C,Negri J,Fanourakis G,Tseleni-Balafouta S,Ain KB,Mitsiades N,Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitroJ Clin Endocrinol MetabYear: 2006914013402110.1210/jc.2005-247216849420|
|Liu D,Xing M,Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathwaysThyroidYear: 20081885386410.1089/thy.2007.035718651802|
|Schweppe RE,Klopper JP,Korch C,Pugazhenthi U,Benezra M,Knauf JA,Fagin JA,Marlow LA,Copland JA,Smallridge RC,Haugen BR,Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentificationJ Clin Endocrinol MetabYear: 2008934331434110.1210/jc.2008-110218713817|
|Karin M,Yamamoto Y,Wang QM,The IKK NF-kappa B system: a treasure trove for drug developmentNat Rev Drug DiscovYear: 20043172610.1038/nrd127914708018|
|Li B,Li YY,Tsao SW,Cheung AL,Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancerMol Cancer TherYear: 200982635264410.1158/1535-7163.MCT-09-016219723887|
|Shishodia S,Sethi G,Konopleva M,Andreeff M,Aggarwal BB,A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cellsClin Cancer ResYear: 2006121828183810.1158/1078-0432.CCR-05-204416551868|
|Deeb D,Gao X,Dulchavsky SA,Gautam SC,CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cellsAnticancer ResYear: 2007273035304417970042|
|Van Antwerp DJ,Martin SJ,Kafri T,Green DR,Verma IM,Suppression of TNF-alpha-induced apoptosis by NF-kappaBScienceYear: 199627478778910.1126/science.274.5288.7878864120|
|Van Antwerp DJ,Verma IM,Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not requiredMol Cell BiolYear: 199616603760458887633|
|Wan YY,DeGregori J,The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expressionImmunityYear: 20031833134210.1016/S1074-7613(03)00053-012648451|
|Luo JL,Kamata H,Karin M,IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapyJ Clin InvestYear: 20051152625263210.1172/JCI2632216200195|
|Hanahan D,Weinberg RA,The hallmarks of cancerCellYear: 2000100577010.1016/S0092-8674(00)81683-910647931|
|Pacifico F,Mauro C,Barone C,Crescenzi E,Mellone S,Monaco M,Chiappetta G,Terrazzano G,Liguoro D,Vito P,Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomasJ Biol ChemYear: 2004279546105461910.1074/jbc.M40349220015475567|
|Kaldis P,Aleem E,Cell cycle sibling rivalry: Cdc2 vs. Cdk2Cell CycleYear: 200541491149416258277|
|Flatt PM,Tang LJ,Scatena CD,Szak ST,Pietenpol JA,p53 regulation of G(2) checkpoint is retinoblastoma protein dependentMol Cell BiolYear: 2000204210422310.1128/MCB.20.12.4210-4223.200010825186|
|Xiao M,Inal CE,Parekh VI,Li XH,Whitnall MH,Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injuryExp HematolYear: 200937526410.1016/j.exphem.2008.09.00118954936|
|Han SW,Roman J,Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa BOncogeneYear: 2006254341434910.1038/sj.onc.120946016518410|
|Raffoul JJ,Wang Y,Kucuk O,Forman JD,Sarkar FH,Hillman GG,Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrestBMC CancerYear: 2006610710.1186/1471-2407-6-10716640785|
|Palona I,Namba H,Mitsutake N,Starenki D,Podtcheko A,Sedliarou I,Ohtsuru A,Saenko V,Nagayama Y,Umezawa K,Yamashita S,BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activationEndocrinologyYear: 20061475699570710.1210/en.2006-040016959844|
|Papenfuss K,Cordier SM,Walczakya H,Death receptors as targets for anti-cancer therapyJ Cell Mol MedYear: 2008122566258510.1111/j.1582-4934.2008.00514.x19210756|
|Papa S,Zazzeroni F,Pham CG,Bubici C,Franzoso G,Linking JNK signaling to NF-kappaB: a key to survivalJ Cell SciYear: 20041175197520810.1242/jcs.0148315483317|
|Tang F,Tang G,Xiang G,Dai Q,Rosner MR,Lin A,The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosisMol Cell BiolYear: 2002228571857910.1128/MCB.22.24.8571-8579.200212446776|
|Bain J,McLauchlan H,Elliott M,Cohen P,The specificities of protein kinase inhibitors: an updateBiochem JYear: 200337119920410.1042/BJ2002153512534346|
|Noutomi T,Itoh M,Toyota H,Takada E,Mizuguchi J,Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cellsOncol RepYear: 2009221169117219787236|
|Stamenkovic I,Matrix metalloproteinases in tumor invasion and metastasisSemin Cancer BiolYear: 20001041543310.1006/scbi.2000.037911170864|
|Min C,Eddy SF,Sherr DH,Sonenshein GE,NF-kappaB and epithelial to mesenchymal transition of cancerJ Cell BiochemYear: 200810473374410.1002/jcb.2169518253935|
|Baldini E,Toller M,Graziano FM,Russo FP,Pepe M,Biordi L,Marchioni E,Curcio F,Ulisse S,Ambesi-Impiombato FS,D'Armiento M,Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell linesThyroidYear: 20041488188810.1089/thy.2004.14.88115671765|
|Duriez PJ,Shah GM,Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell deathBiochem Cell BiolYear: 19977533734910.1139/bcb-75-4-3379493956|
Previous Document: Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clin...
Next Document: Treatment of hepatic encephalopathy by on-line hemodiafiltration: a case series study.